Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top



Oncolytic viruses should be the perfect weapon to beat cancer but trials fail. Our systematic analysis revealed that this is because of delivery challenges, insufficient virus reaches the tumour due to immune response and at the tumour site they are ineffective as they are optimised for lysis rather than immunogenic cell death.



Our team, brought together from £100m+ funded companies in the space, have designed an approach that avoids immune system detection, spreads throughout the cancer and creates an immunogenic cell death both at primary at metastatic sites.